Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.
Bottom Line: In adalimumab-treated patients, greater percentages of NAPSI 50 Responders vs.Non-responders achieved the primary endpoint, and had greater improvements in erythema, scaling, induration and fissuring, Dermatology Life Quality Index, and pain scores.Marked improvement in nail psoriasis among adalimumab-treated patients correlated with significant improvements in skin disease and patient-reported outcomes.
Affiliation: Centre Dermatologique du Québec Métropolitain, Québec, Canada.Show MeSH
Related in: MedlinePlus
Mentions: Among patients with nail psoriasis at baseline, a greater percentage of adalimumab-treated patients (56.5%) compared with placebo-treated patients (12.5%) achieved NAPSI 50 at week 16 (Fig. 3a). Improvement in nail psoriasis at week 16 following treatment with adalimumab is shown in Fig. 4. Further evaluation showed that in adalimumab-treated patients, a greater percentage of NAPSI 50 Responders (61.5%) achieved an hfPGA score of clear or almost clear compared with NAPSI 50 Non-Responders (20.0%) (Fig. 3b). In addition, NAPSI 50 Responders among adalimumab-treated patients demonstrated greater mean percent improvements in ESIF scores (77.6%) and DLQI scores (74.0%) compared with NAPSI 50 Non-Responders (37.2% and 53.6% respectively) (Fig. 3c). Finally, NAPSI 50 Responders experienced a greater mean reduction in pain VAS score (86.1%) than NAPSI 50 Non-Responders (1.4%) among patients treated with adalimumab (Fig. 3c).
Affiliation: Centre Dermatologique du Québec Métropolitain, Québec, Canada.